Time course and significance of acute hyperamylasemia in patients receiving fractionated therapeutic radiation to the parotid gland region

Borok, Thomas L.; Cooper, Jay S.

doi:10.1016/0360-3016(82)90599-5

Cited by 7 publications

(4 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The peak rise in serum amylase was greater in hyperfractionated accelerated schedule than in conventional fractionated RT (mean peak 4477 IU/l and 3275 IU/l, respectively). Similar results were obtained by Kashima et al [ 15 ] and Borok et al [ 16 ]. Kashima et al analyzed 33 patients with HNC cancer and noted a transient hyperamylasemia after a dose range of 1–2.75 Gy, with a peak elevation at 9–36 hours after RT [ 15 ].…”

Section: Introductionsupporting

confidence: 92%

“…Kashima et al analyzed 33 patients with HNC cancer and noted a transient hyperamylasemia after a dose range of 1–2.75 Gy, with a peak elevation at 9–36 hours after RT [ 15 ]. Borok et al measured serum amylase levels in 12 consecutive HNC patients treated with fractionated doses from 1.8 to 4 Gy per day in accordance with patient's needs [ 16 ]. Rapid transient increases in enzyme activity, limited to the first days of RT, were consistently found.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Radiation therapy and serum salivary amylase in head and neck cancer

et al. 2017

View full text Add to dashboard Cite

Radiation therapy (RT) is a valid treatment option for head and neck cancer (HNC). The risk of RT-induced toxicities is significant, especially due to extended treatment fields. The raise in amylase activity is strictly dependent on the volume of salivary glands included in the irradiated target volume and it is firmly related to the dose. The aim of this review is to report the effects on salivary amylase activity after radiation exposure of salivary glands, in patients with HNC.

show abstract

Section: Introductionsupporting

confidence: 92%

Section: Introductionmentioning

confidence: 99%

Radiation therapy and serum salivary amylase in head and neck cancer

et al. 2017

View full text Add to dashboard Cite

show abstract

“…However, we believe that serum salivary amylase activity is valuable to a certain extent to clinical measure. The relationship between serum salivary amylase level and xerostomia is scarcely reported in the scientific literature [ 6 , 12 , 13 , 14 ]. In the past two decades, several clinical trials have been performed to determine the role of salivary amylases in predicting xerostomia.…”

Section: Discussionmentioning

confidence: 99%

Relationship between Salivary Amylase and Xerostomia in Intensity-Modulated Radiation Therapy for Head and Neck Cancer: A Prospective Pilot Study

et al. 2022

View full text Add to dashboard Cite

Purpose. A single-institution prospective pilot study was conducted to the assess correlation between salivary amylase and xerostomia in patients with head and neck squamous cell carcinoma (HNSCC) treated with intensity-modulated radiotherapy (IMRT). Methods and materials. Serum saliva amylase, clinician-reported xerostomia (using Common Terminology Criteria for Adverse Events), and patient-reported xerostomia (using 8-item self-reported xerostomia-specific questionnaire) were prospectively collected at baseline, during treatment and thereafter. Correlations between variables were assessed by correlation matrices. Results. Twelve patients with locally advanced HNSCC formed the cohort. Eighty-three percent were male, 75% were smokers, 100% had clinical positive lymph nodes at diagnosis, and 42% received induction chemotherapy. All patients received IMRT with concurrent cisplatin-based chemotherapy. No grade ≥4 xerostomia was observed. Severe (G3) acute and late xerostomia occurred in five cases (41.7%) and two cases (16.7%), respectively. Patient-reported xerostomia scores were highly correlated with the clinician-reported scores (ρ = 0.73). A significant correlation was recorded between the concentration of amylase and the acute (ρ = −0.70) and late (ρ = −0.80) xerostomia. Conclusion. Preliminary results are encouraging. Prospective clinical trials are needed to define the value of salivary amylase in the management of HNSCC tumors.

show abstract

“…A close relationship between parotid irradiation and blood amylase levels is well-known [ 19 - 21 ], although individual hypervariability has not been associated with dose [ 22 ].…”

Section: Discussionmentioning

confidence: 99%